<a href="https://www.fiercebiotech.com/pharma/ligand-snaps-fellow-biotech-royalty-aggregator-xoma-739m" hreflang="en">Ligand snaps up fellow biotech royalty aggregator Xoma for $739M</a>
Ligand Pharmaceuticals has announced its acquisition of fellow biotech royalty aggregator Xoma for approximately $739 million, which is expected to enhance Ligand's portfolio significantly by adding over 120 assets, including late-stage developments. The deal, set to close in the third quarter of 2026, aims to capitalize on synergies and bolster Ligand's financial outlook, with revised revenue projections following the acquisition.
The acquisition of Xoma by Ligand Pharmaceuticals for $739 million highlights the strategic value of biotech royalty aggregation as a business model, particularly for companies focusing on late-stage and small- to midcap biotechs with unmet medical needs. This move nearly doubles Ligand's portfolio size and is projected to significantly boost its revenue, illustrating a profitable pathway for healthtech investors and companies looking to leverage royalty rights for long-term growth.